Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | DRD1 | P21728 | 3/20 | 0.31 |
| ▸ | DRD4 | P21917 | 3/20 | 0.31 |
| ▸ | DRD5 | P21918 | 3/20 | 0.31 |
| ▸ | DRD3 | P35462 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092754 | 0.90 | — | — | |
| SCHEMBL1092764 | 0.90 | — | — | |
| SCHEMBL4183684 | 0.90 | — | — | |
| SCHEMBL1093101 | 0.84 | SCN1A (0.32) | DRD2DRD4DRD3 | |
| SCHEMBL1091969 | 0.84 | SCN1A (0.32) | DRD2DRD4DRD3 | |
| SCHEMBL208796 | 0.82 | PSEN1 (0.32) | — | |
| SCHEMBL474823 | 0.77 | — | — | |
| SCHEMBL4059636 | 0.76 | — | — | |
| SCHEMBL209385 | 0.76 | — | — | |
| SCHEMBL474702 | 0.75 | FFAR4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2016071-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8148534-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090275613-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275613-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | MEN1 1762/4885ALDH1A1 100/4885TSHR 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.